Pharmaceutical giant Biogen now admits that it made a mistake back in March when it stopped a pair of trials of an experimental Alzheimer’s drug. A deep analysis of the data, released Thursday, suggests the drug, called aducanumab, did make a difference for patients who took the highest dose for the longest period of time—but only in one of two studies.